NASDAQ:CALC CalciMedica (CALC) Stock Price, News & Analysis → Trump’s last act as President (From Porter & Company) (Ad) Free CALC Stock Alerts $5.63 -0.10 (-1.75%) (As of 03:06 PM ET) Add Compare Share Share Today's Range$5.52▼$6.2750-Day Range$3.39▼$5.7352-Week Range$1.75▼$8.59Volume18,850 shsAverage Volume21,142 shsMarket Capitalization$60.47 millionP/E RatioN/ADividend YieldN/APrice Target$18.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get CalciMedica alerts: Email Address CalciMedica MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside231.6% Upside$18.67 Price TargetShort InterestHealthy0.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 2 Articles This WeekInsider TradingAcquiring Shares$2,909 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.04) to ($1.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.69 out of 5 starsMedical Sector240th out of 927 stocksPharmaceutical Preparations Industry99th out of 420 stocks 3.5 Analyst's Opinion Consensus RatingCalciMedica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCalciMedica has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.71% of the float of CalciMedica has been sold short.Short Interest Ratio / Days to CoverCalciMedica has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CalciMedica has recently decreased by 9.68%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCalciMedica does not currently pay a dividend.Dividend GrowthCalciMedica does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CALC. Previous Next 3.3 News and Social Media Coverage News SentimentCalciMedica has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CalciMedica this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for CALC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added CalciMedica to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CalciMedica insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,909.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders53.30% of the stock of CalciMedica is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CalciMedica are expected to grow in the coming year, from ($2.04) to ($1.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CalciMedica is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CalciMedica is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCalciMedica has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. About CalciMedica Stock (NASDAQ:CALC)CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.Read More CALC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CALC Stock News HeadlinesApril 24, 2024 | prnewswire.comCalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute PancreatitisApril 3, 2024 | msn.comCalciMedica And 2 Other Penny Stocks Insiders Are BuyingMay 1, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…March 28, 2024 | finance.yahoo.comCalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate UpdatesMarch 13, 2024 | prnewswire.comCalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT ConferenceFebruary 28, 2024 | finance.yahoo.comCalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT ConferenceFebruary 24, 2024 | msn.comSeaStar’s device granted humanitarian exemption approval for children with AKIFebruary 24, 2024 | msn.comCalciMedica (CALC) Price Target Increased by 61.73% to 16.70May 1, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…February 20, 2024 | it.investing.comSingular Research alza il target del titolo CalciMedica a 9,50 dollari in presenza di un nuovo fondoFebruary 19, 2024 | ca.investing.comCalciMedica stock target raised to $9.50 by Singular Research amid new fundFebruary 14, 2024 | msn.comCalciMedica given FDA approval for Phase II trial of AuxoraFebruary 14, 2024 | markets.businessinsider.comCalciMedica’s Auxora Braces for Phase 2 Trial with Strong Buy Rating from Analyst Joseph PantginisFebruary 13, 2024 | markets.businessinsider.comCalciMedica Announces FDA Clearance Of IND Application For Phase 2 Trial Of AuxoraFebruary 7, 2024 | finance.yahoo.comCalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 28, 2024 | msn.comHuge Insider Buys From Warren Buffett, Jack Ma, Carlos Slim and MoreJanuary 22, 2024 | markets.businessinsider.comCalciMedica Announces Private Offering For Up To About $55 Mln; Stock Down In Pre-marketJanuary 22, 2024 | marketwatch.comCalciMedica Shares Rally After Funding Lined Up for Lead Product CandidateJanuary 22, 2024 | finance.yahoo.comCalciMedica Announces Private Placement of up to Approximately $55 MillionDecember 11, 2023 | finance.yahoo.comCalciMedica Collaborator St. Jude Children's Research Hospital Presents Data from Initial Cohort of CRSPA Study at 65th Annual ASH Meeting & ExpositionNovember 9, 2023 | msn.comCalciMedica GAAP EPS of -$0.82November 9, 2023 | finance.yahoo.comCalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate UpdatesNovember 8, 2023 | msn.comCalciMedia CEO discloses purchase of 2K sharesNovember 7, 2023 | msn.comCalciMedica chief business officer discloses purchase of about 9k sharesNovember 2, 2023 | finance.yahoo.comCalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & ExpositionSeptember 6, 2023 | finance.yahoo.comCalciMedica Announces Upcoming Presentations and Events in SeptemberAugust 31, 2023 | finance.yahoo.comCalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023See More Headlines Receive CALC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CalciMedica and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/01/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CALC CUSIPN/A CIK1534133 Webwww.graybug.vision Phone858-952-5500FaxN/AEmployees14Year FoundedN/APrice Target and Rating Average Stock Price Target$18.67 High Stock Price Target$22.00 Low Stock Price Target$14.00 Potential Upside/Downside+225.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($25.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,360,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-234.70% Return on Assets-165.69% Debt Debt-to-Equity RatioN/A Current Ratio2.88 Quick Ratio2.88 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book4.04Miscellaneous Outstanding Shares10,740,000Free Float5,016,000Market Cap$61.54 million OptionableNo Data Beta1.61 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. A. Rachel Leheny Ph.D. (Age 61)CEO & Director Mr. Eric W. Roberts (Age 60)Chief Business Officer & Vice Chairman of the Board Mr. Michael J. Dunn MBA (Age 68)President & COO Dr. Anjana Rao Ph.D.Co-Founder and Scientific AdvisorDr. Patrick Hogan Ph.D.Co-Founder and Scientific AdvisorDr. Stefan Feske M.D.Co-Founder and Scientific AdvisorDr. Kenneth A. Stauderman Ph.D. (Age 71)Co-Founder & Chief Scientific Officer Mr. Daniel E. Geffken M.B.A. (Age 67)Interim Chief Financial Officer Cindy ReiedenbergAccountantMr. John M. Dunn J.D. (Age 72)General Counsel More ExecutivesKey CompetitorsKronos BioNASDAQ:KRONAnnovis BioNYSE:ANVSMural OncologyNASDAQ:MURAKezar Life SciencesNASDAQ:KZRMediciNovaNASDAQ:MNOVView All CompetitorsInsiders & InstitutionsBML Capital Management LLCBought 15,000 shares on 4/23/2024Ownership: 1.494%Eric W RobertsBought 746 shares on 4/1/2024Total: $2,909.40 ($3.90/share)Meritage Portfolio ManagementBought 36,000 shares on 2/2/2024Ownership: 0.810%Fred A MiddletonBought 679,384 shares on 1/23/2024Total: $2.51 M ($3.70/share)Sanderling Venture Partners ViBought 243,356 shares on 1/23/2024Total: $900,417.20 ($3.70/share)View All Insider TransactionsView All Institutional Transactions CALC Stock Analysis - Frequently Asked Questions Should I buy or sell CalciMedica stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CalciMedica in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CALC shares. View CALC analyst ratings or view top-rated stocks. What is CalciMedica's stock price target for 2024? 3 brokerages have issued 12-month price objectives for CalciMedica's shares. Their CALC share price targets range from $14.00 to $22.00. On average, they anticipate the company's stock price to reach $18.67 in the next twelve months. This suggests a possible upside of 231.6% from the stock's current price. View analysts price targets for CALC or view top-rated stocks among Wall Street analysts. How have CALC shares performed in 2024? CalciMedica's stock was trading at $2.86 at the beginning of 2024. Since then, CALC stock has increased by 96.9% and is now trading at $5.63. View the best growth stocks for 2024 here. Are investors shorting CalciMedica? CalciMedica saw a decline in short interest in April. As of April 15th, there was short interest totaling 33,600 shares, a decline of 9.7% from the March 31st total of 37,200 shares. Based on an average daily volume of 23,000 shares, the short-interest ratio is currently 1.5 days. Currently, 0.7% of the company's stock are short sold. View CalciMedica's Short Interest. When is CalciMedica's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our CALC earnings forecast. How were CalciMedica's earnings last quarter? CalciMedica, Inc. (NASDAQ:CALC) released its earnings results on Thursday, March, 28th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.77. Who are CalciMedica's major shareholders? CalciMedica's stock is owned by a number of retail and institutional investors. Top institutional investors include BML Capital Management LLC (1.49%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include A Rachel Leheny, Eric W Roberts, Fred A Middleton, Robert N Wilson and Sanderling Venture Partners Vi. View institutional ownership trends. How do I buy shares of CalciMedica? Shares of CALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CALC) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Report😱 This phenomenon is smashing regular market gainsMillPubForget Nvidia. This is the future of AIPorter & CompanyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
